Literature DB >> 2860942

Which component of sulphasalazine is active in rheumatoid arthritis?

T Pullar, J A Hunter, H A Capell.   

Abstract

Sulphasalazine is known to be effective as a second line agent in the treatment of rheumatoid arthritis. The two chemical constituents of sulphasalazine (sulphapyridine and 5-aminosalicylic acid) were assessed separately in the treatment of rheumatoid arthritis. Over 24 weeks sulphapyridine showed a pronounced second line effect comparable with sulphasalazine and with a similar toxicity profile, whereas 5-aminosalicylic acid showed only a weak first line effect. Thus sulphapyridine appears to be the active moiety responsible for the second line effect of sulphasalazine in rheumatoid arthritis. The efficacy of the antibacterial component of sulphasalazine yet again permits speculation about the role of a bacterial pathogen in the aetiopathogenesis of rheumatoid disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860942      PMCID: PMC1415752          DOI: 10.1136/bmj.290.6481.1535

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  12 in total

1.  Salazopyrin in the Treatment of Rheumatoid Arthritis.

Authors:  R J Sinclair; J J Duthie
Journal:  Ann Rheum Dis       Date:  1949-09       Impact factor: 19.103

2.  A biochemical assessment of sulphasalazine in rheumatoid arthritis.

Authors:  H A Bird; J S Dixon; M E Pickup; V M Rhind; J R Lowe; M R Lee; V Wright
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

3.  A human model screening system for the detection of specific antirheumatic activity.

Authors:  J S Dixon; H A Bird; M E Pickup; V Wright
Journal:  Semin Arthritis Rheum       Date:  1982-11       Impact factor: 5.532

Review 4.  A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question?

Authors:  T Pullar; H A Capell
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

5.  Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis.

Authors:  W C KUZELL; G M GARDNER
Journal:  Calif Med       Date:  1950-12

6.  Malaria vaccination: two steps forward, one backward.

Authors:  W Peters
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

7.  Prenatal development of lumbar intervertebral articulation.

Authors:  M Med
Journal:  Folia Morphol (Praha)       Date:  1982

Review 8.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 9.  Sulphasalazine: a 'new' antirheumatic drug.

Authors:  T Pullar; H A Capell
Journal:  Br J Rheumatol       Date:  1984-02

10.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16
View more
  35 in total

Review 1.  Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis?

Authors:  J R O'Dell
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 2.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis.

Authors:  J Elmgreen; O H Nielsen; I Ahnfelt-Rønne
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

Review 4.  Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis.

Authors:  Christopher Chidley; Hirohito Haruki; Miriam Grønlund Pedersen; Evelyne Muller; Kai Johnsson
Journal:  Nat Chem Biol       Date:  2011-04-17       Impact factor: 15.040

6.  HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.

Authors:  H Bliddal; B Eiberg; P Helin; A Svejgaard
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

7.  Sulphasalazine for rheumatoid arthritis. Studies on dose, acetylator phenotype and efficacy.

Authors:  R S Amos; D E Bax; M S Greaves
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 8.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.

Authors:  A J Taggart; B J McDermott; S D Roberts
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.

Authors:  P Sheldon; P Pell
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.